Results 171 to 180 of about 29,778 (296)

Natriuretic Peptides and the Kidney

open access: yes, 1994
The years since 1981 have witnessed numerous studies characterizing and defining the roles of several natriuretic peptides that partici- pate in the regulation of volume homeostasis in animals and human beings.
Gerzer, R., Epstein, M. (1)
core  

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad   +9 more
wiley   +1 more source

Machine learning to optimize the diagnostic performance of natriuretic peptides for acute heart failure across age groups. [PDF]

open access: yesESC Heart Fail
Perez Vicencio D   +37 more
europepmc   +1 more source

Flexible wearable electronics for cardiovascular monitoring from surface signals to deep physiological insights

open access: yesFlexMat, EarlyView.
This review organizes flexible wearable electronics for cardiovascular monitoring into four interconnected information layers: surface electrophysiology, hemodynamic sensing, vascular imaging, and biofluid biomarker analysis. This framework clarifies how electrical rhythm, vascular loading, structural and flow‐related features, and biochemical states ...
Qiao Chen   +5 more
wiley   +1 more source

Natriuretic peptides as novel regulators of dendritic cells-mediated inflammation. [PDF]

open access: yesCell Mol Life Sci
Manni G   +9 more
europepmc   +1 more source

Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)

open access: yesiMetaMed, EarlyView.
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou   +6 more
wiley   +1 more source

Early gut microbial and metabolic dysregulation with subclinical cardiac alterations in a nonhuman primate model of Rett syndrome

open access: yesiMeta, EarlyView.
Longitudinal multi‐omics profiling of a nonhuman primate Rett syndrome (RTT) model reveals early systemic alterations. RTT monkeys exhibited postnatal growth retardation, intestinal structural abnormalities, and low‐grade systemic inflammation. Gut microbiome analysis showed delayed microbial maturation and age‐discordant dysbiosis, including altered ...
Ting Zhang   +8 more
wiley   +1 more source

Iron deficiency in heart failure: Epidemiology, diagnostic criteria and treatment modalities

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 723-726, April 2025.
Stephan von Haehling
wiley   +1 more source

Home - About - Disclaimer - Privacy